Cronos Group Stock Price, News & Analysis

Cronos Group (NASDAQ: CRON) reported strong Q1 2025 results with net revenue increasing 28% year-over-year to $32.3 million. The company achieved a net income of $7.7 million, a significant improvement from a $2.4 million loss in Q1 2024. Gross profit surged 206% to $13.7 million, with gross margin expanding to 43%. The company maintains a robust balance sheet with $838 million in cash and investments. Spinach® brand holds leading positions in Canada: #1 in edibles, #3 in flower, and #4 in vapes. PEACE NATURALS® retained its #1 position in Israel. The Board authorized a $50 million share repurchase program starting May 14, 2025. The Cronos GrowCo expansion is on track for completion in Q2 2025. However, the company faces potential challenges in Israel with proposed tariffs of up to 165% on Canadian medical cannabis imports.

Cronos Group (NASDAQ: CRON) (TSX: CRON) has announced its upcoming 2025 Annual Meeting of Shareholders, scheduled for Friday, June 20, 2025, at 11:00 a.m. ET. The meeting will be conducted in a virtual-only format through a live audio webcast.

Key Meeting Details:

• Shareholders and proxyholders can participate remotely regardless of location
• Participants will have opportunities to ask questions and vote
• Meeting access available at virtualshareholdermeeting.com/CRON2025
• Detailed instructions and formal business agenda available on Cronos investor relations website

A replay of the Annual Meeting will be accessible through the company's investor relations website approximately 24 hours after the event concludes. The virtual format ensures equal participation opportunities for all registered shareholders and appointed proxyholders.

Cronos Group (NASDAQ: CRON) (TSX: CRON) has scheduled its 2025 first quarter earnings conference call for Thursday, May 8, 2025, at 8:30 a.m. ET. The company's senior management will present financial results and take questions from the investment community following prepared remarks.

Interested participants can register for the conference call and webcast through the company's investor relations website at https://ir.thecronosgroup.com/events-presentations. To ensure timely access, participants are encouraged to dial in fifteen minutes before the scheduled start time. A replay of the webcast will be made available on Cronos' website after the event.

Cronos Group (NASDAQ: CRON) has announced the launch of new cannabis products under its Spinach® brand, introducing three new 1.2g vape products and expanding its SOURZ by Spinach® edible line.

The new vape lineup features:

• Mango Kiwi Haze CBC (Sativa) with 1:10 CBC-to-THC ratio
• Peach Passionfruit Kush CBN (Indica) with 1:10 CBN-to-THC ratio
• Strawberry Watermelon OG CBG (Hybrid) with 1:10 CBG-to-THC ratio

Each vape contains 1,000mg of THC and features winterized, distilled cannabis extract with ceramic heaters and stainless steel components. The SOURZ by Spinach® Fully Blasted lineup includes new 10mg THC gummies enhanced with rare cannabinoids in three flavors: Mango Lime (with CBC), Peach Passionfruit (with CBN), and Strawberry Watermelon (with CBG).

Cronos Group (NASDAQ: CRON) has appointed Anna Shlimak as Chief Financial Officer, effective March 19, 2025. Shlimak, previously serving as Chief Strategy Officer, succeeds James Holm who will remain with the company through April 18, 2025 to ensure a smooth transition.

Shlimak has been a key member of Cronos' leadership team for seven years, where she has led strategic initiatives in cost optimization, revenue growth, and corporate brand building. CEO Mike Gorenstein expressed confidence in Shlimak's ability to drive financial strategy and growth, citing her deep understanding of the business and track record in driving financial performance.

James Holm, departing after two and a half years, will pursue other opportunities after contributing to improving the company's finance functions and building a robust finance team.

Cronos Group (NASDAQ: CRON) (TSX: CRON), a global cannabinoid company, has announced its participation in the upcoming 37th Annual Roth Conference. Mike Gorenstein, who serves as Chairman, President and CEO, will deliver a presentation on Monday, March 17, 2025, at 1:00 PM PT.

Investors and interested parties can access a live webcast of the presentation through the Investors section of Cronos Group's website at ir.thecronosgroup.com/events-presentations.

Cronos Group (NASDAQ: CRON) reported strong financial results for Q4 and full-year 2024, with Q4 net revenue increasing 27% year-over-year to $30.3 million and full-year revenue up 35% to $117.6 million.

Key highlights include:

• Spinach® ended 2024 as the #1 cannabis brand in Canada, with 5.7% market share in flower category
• PEACE NATURALS® achieved #1 position in Israel with 24% market share
• Company maintains strong balance sheet with $859 million in cash
• Q4 2024 gross profit increased to $10.8 million, up from $1.9 million in Q4 2023
• Adjusted EBITDA improved to $(7.2) million in Q4 2024, a $7.6 million improvement year-over-year

The company expanded operations through Cronos GrowCo investment, enhanced cultivation capabilities, and strengthened international presence in Germany and UK markets.

Cronos Group (NASDAQ: CRON) (TSX: CRON) has announced its upcoming 2024 fourth-quarter and full-year earnings conference call, scheduled for Thursday, February 27, 2025, at 8:30 a.m. ET.

The company's senior management team will present financial results and participate in a Q&A session with the investment community.

Interested participants are encouraged to register online at the company's investor relations website and dial in fifteen minutes before the scheduled start time to avoid delays. The webcast will be archived on Cronos' website for later viewing.

Cronos Group (NASDAQ: CRON) reported strong Q3 2024 results with net revenue increasing 38% year-over-year to $34.3 million. The Spinach® brand became the #1 cannabis brand in Canada, leading in edibles with 17.2% market share. The company maintains a robust balance sheet with $862 million in cash and cash equivalents. Cronos completed its investment in Cronos GrowCo, gaining majority board control and consolidating results from July 2024. Despite a gross profit decrease of 9% to $3.6 million, Adjusted Gross Profit increased 170% to $10.7 million, and Adjusted EBITDA improved by 60% to $(6.0) million.